ClinicalTrials.gg
Status unknownNCT03524209COROSIVEUpdated Jun 30, 2022

CORset Versus OstéoSynthese in Adult Pyogenic Spondylodiscitis

An interventional study of Percutaneous instrumentation of the thoracolumbar spine and Brace in Spondylodiscitis, sponsored by University Hospital, Strasbourg, France. Status unknown at 15 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-30.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Pyogenic spondylitis in adults is usually treated by antibiotics according to bacteria evidenced in a diagnostic intervertebral disc puncture. Brace treatment is associated in patients presenting back pain and a risk for vertebral body collapse due to infection with subsequent kyphotic deformity of the thoracolumbar spine. Percutaneous minimally invasive posterior spinal instrumentation has evolved over the last decade and indications in infections arouse over the last years. This procedure is interesting as it is performed through small skin incisions only. It avoids paravertebral muscle dissection and thus limits intraoperative bleeding and access morbidity. Recent retrospective data suggests that this internal fixation represents a theoretical advantage over brace treatment by lowering back pain and increasing patient's quality of life in the short run, up to 3 months, but no randomized study was published. The patient's autonomy, including walking ability and daily activities, might improve more rapidly after a percutaneous procedure. Additionally, the sagittal alignment of the thoracolumbar spine could be better maintained by internal fixation, which might prevent progression into kyphosis and improve long-term outcome. The hypothesis is the superiority of percutaneous minimally invasive instrumentation on brace treatment in term of quality of life, back pain and quality of osseous healing.

Read the detailed description

Safety and efficacy of percutaneous for the indication of pyogenic spondylitis has been demonstrated retrospectively on small cohort studies, which is in line with our clinical experience. Although this therapeutic concept seems applicable to patients with spondylitis, the theoretical clinical benefit of minimally invasive surgery remains hypothetic and unclear compared to brace treatment, which might still be regarded as the gold standard.

02

Conditions studied

  • Spondylodiscitis

Browse trials for

Keywords

  • Spondylodiscitis
  • spinal infection
  • back pain
  • quality of life
  • fusion
  • minimal invasive surgery
  • brace treatment
03

In context

Discitis

24 studies on the registry are indexed under Discitis; 5 are open to participants now.

Browse Discitis studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients presenting acute pyogenic spondylitis of the thoracolumbar spine
  • back pain at a minimum of 4 out of 10 on VAS
  • Diagnostic MRI and disc puncture + microbiological analysis required for antibiotic treatment and/or blood culture
  • Vertebral body involvement (osteolysis) \< 50% of VB height documented on CT

Exclusion criteria

Exclusion criteria:

  • postoperative pyogenic spondylitis or infection after spinal instrumentation spinal tuberculosis and mycosis
  • for surgery or general anaesthesia
  • general septic conditions acute endocarditis documented by sonography
  • patients presenting another major abcess or an epidural abscess
  • Absence of vertebral body involvement (osteolysis) on CT or minor VB involvement less than 10% of VB height (surgery not indicated)
  • Major destruction of vertebral body (>50%) on CT (surgery mandatory) Patients with concomitant bacterial endocarditis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    Surgery

    Patients with spondylodiscitis are operated by percutaneous instrumentation and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)

    Device: Percutaneous instrumentation of the thoracolumbar spine

  • Other
    Brace

    Patients with spondylodiscitis are wearing a thoracolumbar brace for 3 months and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)

    Other: Brace

Interventions

  • DevicePercutaneous instrumentation of the thoracolumbar spine

    The spine is stabilized cranially and caudally of the level of spondylodiscitis. The percutaneous instrumentation consists of a rod and pedicle screw construct. The vertebrae are instrumented through minimal skin incisions using a fluoroscopic guidance or a spinal navigation system based on 3D imaging.

    Also known as: minimal invasive surgery (MIS)

  • OtherBrace

    Brace treatment is associated in patients presenting back pain and a risk for vertebral body collapse due to infection with subsequent kyphotic deformity of the thoracolumbar spine

06

What researchers measure

Primary outcomes

  1. Comparison of VAS for back pain for brace versus percutaneous instrumentation

    VAS score from 0 to 10 filled out by patients for clinical evaluation of primary outcome measure (pain)

    Time frame: Pre treatment

  2. Comparison of VAS for back pain for brace versus percutaneous instrumentation

    VAS score from 0 to 10 filled out by patients for clinical evaluation of primary outcome measure (pain)

    Time frame: Post treatment day 5

  3. Comparison of VAS for back pain for brace versus percutaneous instrumentation

    VAS score from 0 to 10 filled out by patients for clinical evaluation of primary outcome measure (pain)

    Time frame: Post treatment 6 weeks

  4. Comparison of VAS for back pain for brace versus percutaneous instrumentation

    VAS score from 0 to 10 filled out by patients for clinical evaluation of primary outcome measure (pain)

    Time frame: Post treatment 3 months

  5. Comparison of VAS for back pain for brace versus percutaneous instrumentation

    VAS score from 0 to 10 filled out by patients for clinical evaluation of primary outcome measure (pain)

    Time frame: Post treatment 6 months

  6. Comparison of VAS for back pain for brace versus percutaneous instrumentation

    VAS score from 0 to 10 filled out by patients for clinical evaluation of primary outcome measure (pain)

    Time frame: Post treatment 1 year

  7. Comparison of VAS for back pain for brace versus percutaneous instrumentation

    VAS score from 0 to 10 filled out by patients for clinical evaluation of primary outcome measure (pain)

    Time frame: Post treatment 2 years

Secondary outcomes

  1. Comparison of quality of life (QoL) by EQ-5D for brace versus percutaneous instrumentation

    EQ-5D-3L questionnaire filled out by the patients

    Time frame: Change of score between pre treatment and during 2 years after treatment

  2. - Comparison of influence of both treatment on kyphotic deformity - Comparison of fusion rates versus pseudarthrosis for both treatments

    Radiographic measurements by modified sagittal index on lateral radiographs in standing position

    Time frame: Change of measures between pre treatment and during 2 years after treatment

  3. Analysis of correlation between kyhphosis / fusion and VAS / QoL scores

    Radiographic measurements by modified sagittal index on lateral radiographs in standing position

    Time frame: Change of measures between pre treatment and during 2 years after treatment

  4. Course of CRP

    Routine blood tests for documentation of CRP

    Time frame: Change of value between pre treatment and during 3 months after treatment

  5. Documentation of secondary complications after percutaneous instrumentation

    Comparison of influence of both treatment

    Time frame: Change between pre treatment and during 2 years after treatment

Other outcomes

  1. Documentation, reporting and analysis of potential complications

    Comparison of influence of both treatment

    Time frame: Change between pre treatment and during 2 years after treatment

07

Study locations

15 sites
  • CHU de Bordeaux - Hôpital Pellegrin - Unité d'orthopédie-traumatologie rachis I
    Bordeaux, 33076, France
  • CHU de CAEN
    Caen, 14033, France
  • Hôpital Beaujon - Service de Chirurgie Orthopédique et Traumatologie
    Clichy, 92110, France
  • CHU François Mitterand - Bocage central - Service de Neurochirurgie
    Dijon, 21079, France
  • CHU de GRENOBLE
    Grenoble, 38043, France
  • CHU Lyon - Hôpital Pierre Wertheimer - Service de Neurochirurgie C et chirurgie du rachis
    Lyon, 69003, France
  • CHU Marseille - Hôpital Timone - Service de chirurgie orthopédique et traumatologique
    Marseille, 13005, France
  • Hôpital Gui de Chauliac - Service de Neurochirurgie
    Montpellier, 34090, France
  • Hôpital Central - Service de Neurochirurgie
    Nancy, 54035, France
  • CHU Hôtel Dieu - Service de Neurotraumatologie
    Nantes, 44093, France
  • CHU Nice - Hôpital Pasteur 2 - Unité de Chirurgie Rachidienne
    Nice, 06001, France
  • Hôpital Pitié - Salpêtrière - Service de Chirurgie orthopédique
    Paris, 75013, France
  • Hôpital européen Georges-Pompidou - Service d'Orthopédie/Traumotologie
    Paris, 75015, France
  • CHU Reims - Hôpital Maison Blanche - Service de Neurochirurgie
    Reims, 45092, France
  • Hôpitaux Universitaires de Strasbourg - Service de chirurgie du rachis
    Strasbourg, 67091, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03524209
Responsible party
Sponsor
First posted
May 14, 2018
Start date
Aug 21, 2019
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Jun 30, 2022

Study contacts

Yann Philippe CHARLES, MD
principal investigator · Hôpitaux Universitaires de Strasbourg - Service de chirurgie du rachis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion